{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T22:06:20Z","timestamp":1781215580281,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2306800"],"award-info":[{"award-number":["2023YFC2306800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Major Research Plan of Key Research and Development Project of Zhejiang Province","award":["2024C03149"],"award-info":[{"award-number":["2024C03149"]}]},{"name":"Hainan Province Science and Technology Special Fund","award":["ZDYF2025LCLH012"],"award-info":[{"award-number":["ZDYF2025LCLH012"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["92159202"],"award-info":[{"award-number":["92159202"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-12178-1","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T14:30:19Z","timestamp":1753281019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic nomogram for recurrence of hepatocellular carcinoma after liver transplantation for decision making on postoperative adjuvant therapy"],"prefix":"10.1038","volume":"15","author":[{"given":"Chen-Hao","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Yu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Xin","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Wun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Zhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Sen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"issue":"3","key":"12178_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (3), 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"issue":"10204","key":"12178_CR2","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","volume":"394","author":"M Zhou","year":"2019","unstructured":"Zhou, M. et al. Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: A systematic analysis for the global burden of disease study 2017. Lancet 394 (10204), 1145\u20131158 (2019).","journal-title":"Lancet"},{"issue":"2","key":"12178_CR3","first-page":"87","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65 (2), 87\u2013108 (2015).","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"12178_CR4","first-page":"115","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen, W. et al. Cancer statistics in china, 2015. CA Cancer J. Clin. 66 (2), 115\u2013132 (2016).","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"12178_CR5","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1245\/s10434-014-4273-6","volume":"22","author":"G Sapisochin","year":"2015","unstructured":"Sapisochin, G. et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series. Ann. Surg. Oncol. 22 (7), 2286\u20132294 (2015).","journal-title":"Ann. Surg. Oncol."},{"issue":"4","key":"12178_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/lt.24742","volume":"23","author":"E Fernandez-Sevilla","year":"2017","unstructured":"Fernandez-Sevilla, E. et al. Recurrence of hepatocellular carcinoma after liver transplantation: is there a place for resection? Liver Transpl. 23 (4), 440\u2013447 (2017).","journal-title":"Liver Transpl."},{"issue":"11","key":"12178_CR7","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1007\/s00259-021-05328-w","volume":"48","author":"W Miao","year":"2021","unstructured":"Miao, W. et al. An FDG PET\/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation. Eur. J. Nucl. Med. Mol. Imaging. 48 (11), 3656\u20133665 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"12178_CR8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jhep.2018.12.029","volume":"70","author":"N Goldaracena","year":"2019","unstructured":"Goldaracena, N. et al. Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation. J. Hepatol. 70 (4), 666\u2013673 (2019).","journal-title":"J. Hepatol."},{"issue":"2","key":"12178_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/ajt.15697","volume":"20","author":"EC Verna","year":"2020","unstructured":"Verna, E. C. et al. Liver transplantation for hepatocellular carcinoma: management after the transplant. Am. J. Transpl. 20 (2), 333\u2013347 (2020).","journal-title":"Am. J. Transpl."},{"issue":"8","key":"12178_CR10","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1097\/TP.0000000000003434","volume":"105","author":"N El-Domiaty","year":"2021","unstructured":"El-Domiaty, N. et al. Early versus late hepatocellular carcinoma recurrence after transplantation: predictive factors, patterns, and Long-term outcome. Transplantation 105 (8), 1778\u20131790 (2021).","journal-title":"Transplantation"},{"issue":"11","key":"12178_CR11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJM199603143341104","volume":"334","author":"V Mazzaferro","year":"1996","unstructured":"Mazzaferro, V. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl. J. Med. 334 (11), 693\u2013699 (1996).","journal-title":"N Engl. J. Med."},{"issue":"3","key":"12178_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4254\/wjh.v11.i3.261","volume":"11","author":"NA Filgueira","year":"2019","unstructured":"Filgueira, N. A. Hepatocellular carcinoma recurrence after liver transplantation: risk factors, screening and clinical presentation. World J. Hepatol. 11 (3), 261\u2013272 (2019).","journal-title":"World J. Hepatol."},{"issue":"6","key":"12178_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.hbpd.2022.05.013","volume":"21","author":"JW Zhao","year":"2022","unstructured":"Zhao, J. W. et al. Prediction of early recurrence of hepatocellular carcinoma after liver transplantation based on computed tomography radiomics nomogram. Hepatobiliary Pancreat. Dis. Int. 21 (6), 543\u2013550 (2022).","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"issue":"4","key":"12178_CR14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/01.sla.0000250453.34507.d3","volume":"245","author":"J Xu","year":"2007","unstructured":"Xu, J. et al. Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery. Ann. Surg. 245 (4), 583\u2013590 (2007).","journal-title":"Ann. Surg."},{"issue":"8","key":"12178_CR15","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1055\/s-2007-963717","volume":"46","author":"J Trojan","year":"2008","unstructured":"Trojan, J. et al. Neoadjuvant treatment with cetuximab, 5-fluorouracil, folinic acid and oxaliplatin in unresectable retroperitoneal recurrent colon cancer. Z. Gastroenterol. 46 (8), 776\u2013779 (2008).","journal-title":"Z. Gastroenterol."},{"issue":"10","key":"12178_CR16","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1200\/JCO.22.01142","volume":"41","author":"SH Li","year":"2023","unstructured":"Li, S. H. et al. Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: A multicenter, phase III, randomized study. J. Clin. Oncol. 41 (10), 1898\u20131908 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"12178_CR17","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1245\/s10434-020-08601-8","volume":"27","author":"S Li","year":"2020","unstructured":"Li, S. et al. Postoperative adjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of hepatocellular carcinoma patients with microvascular invasion: A preliminary report of a phase III, randomized controlled clinical trial. Ann. Surg. Oncol. 27 (13), 5183\u20135190 (2020).","journal-title":"Ann. Surg. Oncol."},{"issue":"24","key":"12178_CR18","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.1158\/1078-0432.CCR-23-0060","volume":"29","author":"M He","year":"2023","unstructured":"He, M. et al. Lenvatinib, Toripalimab plus FOLFOX chemotherapy in hepatocellular carcinoma patients with extrahepatic metastasis: A biomolecular exploratory, phase II trial (LTSC). Clin. Cancer Res. 29 (24), 5104\u20135115 (2023).","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"12178_CR19","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl. J. Med. 359 (4), 378\u2013390 (2008).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"12178_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng, A. L. et al. Efficacy and safety of Sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10 (1), 25\u201334 (2009).","journal-title":"Lancet Oncol."},{"issue":"5","key":"12178_CR21","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/annonc\/mdy510","volume":"30","author":"A Vogel","year":"2019","unstructured":"Vogel, A. et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30 (5), 871\u2013873 (2019).","journal-title":"Ann. Oncol."},{"issue":"2","key":"12178_CR22","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero, J. A. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology 68 (2), 723\u2013750 (2018).","journal-title":"Hepatology"},{"issue":"1","key":"12178_CR23","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European association for the study of the liver. EASL clinical practice guidelines. EASL clinical practice guidelines. management of hepatocellular carcinoma. J. Hepatol. 69 (1), 182\u2013236 (2018).","journal-title":"J. Hepatol."},{"issue":"4","key":"12178_CR24","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/hep.29907","volume":"68","author":"DJ Firl","year":"2018","unstructured":"Firl, D. J. et al. Reframing the approach to patients with hepatocellular carcinoma: longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy. Hepatology 68 (4), 1448\u20131458 (2018).","journal-title":"Hepatology"},{"issue":"4","key":"12178_CR25","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jamcollsurg.2014.12.025","volume":"220","author":"VG Agopian","year":"2015","unstructured":"Agopian, V. G. et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J. Am. Coll. Surg. 220 (4), 416\u2013427 (2015).","journal-title":"J. Am. Coll. Surg."},{"issue":"4","key":"12178_CR26","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jhep.2010.12.040","volume":"55","author":"S Merani","year":"2011","unstructured":"Merani, S. et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J. Hepatol. 55 (4), 814\u2013819 (2011).","journal-title":"J. Hepatol."},{"issue":"4","key":"12178_CR27","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1053\/j.gastro.2012.05.052","volume":"143","author":"C Duvoux","year":"2012","unstructured":"Duvoux, C. et al. Liver transplantation for hepatocellular carcinoma: A model including \u03b1-fetoprotein improves the performance of Milan criteria. Gastroenterology 143 (4), 986\u2013994e3 (2012).","journal-title":"Gastroenterology"},{"issue":"3","key":"12178_CR28","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/SLA.0b013e318148c704","volume":"246","author":"JP Duffy","year":"2007","unstructured":"Duffy, J. P. et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: A 22-year experience with 467 patients at UCLA. Ann. Surg. 246 (3), 502\u2013509 (2007). discussion 9\u201311.","journal-title":"Ann. Surg."},{"issue":"10","key":"12178_CR29","first-page":"527","volume":"12","author":"GC Sotiropoulos","year":"2007","unstructured":"Sotiropoulos, G. C. et al. Meta-analysis of tumor recurrence after liver transplantation for hepatocellular carcinoma based on 1,198 cases. Eur. J. Med. Res. 12 (10), 527\u2013534 (2007).","journal-title":"Eur. J. Med. Res."},{"issue":"5","key":"12178_CR30","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s11605-018-3688-y","volume":"22","author":"A Vitale","year":"2018","unstructured":"Vitale, A. et al. Utility of tumor burden score to stratify prognosis of patients with hepatocellular cancer: results of 4759 cases from ITA.LI.CA study group. ITA.LI.CA. ITA.li. J. Gastrointest. Surg. 22 (5), 859\u2013871 (2018).","journal-title":"J. Gastrointest. Surg."},{"issue":"3","key":"12178_CR31","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1159\/000485396","volume":"44","author":"J Zheng","year":"2017","unstructured":"Zheng, J. et al. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: A meta-analysis and systematic review. Cell. Physiol. Biochem. 44 (3), 967\u2013981 (2017).","journal-title":"Cell. Physiol. Biochem."},{"issue":"15","key":"12178_CR32","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.3748\/wjg.v24.i15.1658","volume":"24","author":"Q Lai","year":"2018","unstructured":"Lai, Q. et al. Platelet-to-lymphocyte ratio in the setting of liver transplantation for hepatocellular cancer: A systematic review and meta-analysis. World J. Gastroenterol. 24 (15), 1658\u20131665 (2018).","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"12178_CR33","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S1499-3872(15)60373-3","volume":"14","author":"HS Lin","year":"2015","unstructured":"Lin, H. S. et al. Adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma: A systematic review and a meta-analysis. Hepatobiliary Pancreat. Dis. Int. 14 (3), 236\u2013245 (2015).","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"issue":"6","key":"12178_CR34","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1007\/s10637-011-9726-1","volume":"29","author":"Q Zhang","year":"2011","unstructured":"Zhang, Q. et al. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: A preliminary open-label study. Invest. New. Drugs. 29 (6), 1360\u20131369 (2011).","journal-title":"Invest. New. Drugs"},{"issue":"4","key":"12178_CR35","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1432-2277.2006.00279.x","volume":"19","author":"G S\u00f6derdahl","year":"2006","unstructured":"S\u00f6derdahl, G. et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl. Int. 19 (4), 288\u2013294 (2006).","journal-title":"Transpl. Int."},{"issue":"2","key":"12178_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/ctr.12042","volume":"27","author":"M Fujiki","year":"2013","unstructured":"Fujiki, M., Aucejo, F. & Kim, R. Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this? Clin. Transpl. 27 (2), 169\u2013177 (2013).","journal-title":"Clin. Transpl."},{"issue":"10","key":"12178_CR37","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","volume":"7","author":"SM Wilhelm","year":"2008","unstructured":"Wilhelm, S. M. et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7 (10), 3129\u20133140 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"12178_CR38","first-page":"913634","volume":"2014","author":"K Shetty","year":"2014","unstructured":"Shetty, K., Dash, C. & Laurin, J. Use of adjuvant Sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma. J. Transpl. 2014, 913634 (2014).","journal-title":"J. Transpl."},{"issue":"2","key":"12178_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000367734","volume":"4","author":"AB Siegel","year":"2015","unstructured":"Siegel, A. B. et al. Phase I trial of Sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma. Liver Cancer. 4 (2), 115\u2013125 (2015).","journal-title":"Liver Cancer"},{"issue":"5","key":"12178_CR40","doi-asserted-by":"publisher","first-page":"e13246","DOI":"10.1111\/ctr.13246","volume":"32","author":"SK Satapathy","year":"2018","unstructured":"Satapathy, S. K. et al. No apparent benefit of preemptive Sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant. Clin. Transpl. 32 (5), e13246 (2018).","journal-title":"Clin. Transpl."},{"key":"12178_CR41","doi-asserted-by":"publisher","first-page":"562103","DOI":"10.3389\/fonc.2020.562103","volume":"10","author":"B Han","year":"2020","unstructured":"Han, B. et al. Potential role of adjuvant lenvatinib in improving disease-free survival for patients with high-risk hepatitis B virus-related hepatocellular carcinoma following liver transplantation: A retrospective, case control study. Front. Oncol. 10, 562103 (2020).","journal-title":"Front. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12178-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12178-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12178-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T21:26:37Z","timestamp":1757280397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12178-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12178"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12178-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by institutional ethics committees of the Shulan (Hangzhou) Hospital, The First Affiliated Hospital of the University of Science and Technology of China, and Huashan Hospital of Fudan University, and informed consent was waived by institutional ethics committees of the Shulan (Hangzhou) Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"26792"}}